AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 290: H2424-H2431, 2006; doi:10.1152/ajpheart.00962.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leshnower, B. G.
Right arrow Articles by Gorman, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leshnower, B. G.
Right arrow Articles by Gorman, R. C.

Role of acetaminophen in acute myocardial infarction

Bradley G. Leshnower,1,* Hiroaki Sakamoto,1,* Ahmad Zeeshan,1 Landi M. Parish,1 Robin Hinmon,1 Theodore Plappert,2 Benjamin M. Jackson,1 Joseph H. Gorman, III,1 and Robert C. Gorman1

1Harrison Department of Surgical Research and 2Division of Cardiology, Department of Medicine, University Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Submitted 8 September 2005 ; accepted in final form 12 January 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Acetaminophen, the active ingredient in Tylenol, is a widely used drug that is well known for its analgesic and antipyretic properties. Acetaminophen is a commonly used alternative to nonsteroidal anti-inflammatory drugs, which have recently been demonstrated to increase mortality after acute myocardial infarction (AMI). The safety and potential cardioprotective properties of acetaminophen in the setting of AMI have recently been investigated; however, the results from these studies have been inconclusive. Using both large (ovine) and small (rabbit) collateral-deficient animal models, we studied the effects of acetaminophen in the setting of reperfused AMI. In both species we studied the effects of acetaminophen on myocardial salvage and ventricular function. Additionally, we studied the effects of acetaminophen on myocardial perfusion in sheep and on myocyte apoptosis in rabbits. Sixteen sheep and twenty-two rabbits were divided into two groups and administered acetaminophen or a vehicle before undergoing ischemia and reperfusion. The ischemic period was 60 min in sheep and 30 min in rabbits. All animals were reperfused for 3 h. There were no significant differences observed in myocardial perfusion, myocyte apoptosis, or infarct size in acetaminophen-treated animals. Acetaminophen increased cardiac output and mean arterial pressure before ischemia in sheep but had no effect on any other hemodynamic parameter. In rabbits, no effect on cardiac output or blood pressure was detected. These results support the role of acetaminophen as a safe drug in the postmyocardial infarction setting; however, no significant cardioprotective effect of the drug could be demonstrated.

reperfusion therapy; nonsteroidal anti-inflammatory drugs; sonomicrometry array localization

RECENTLY, A NUMBER OF STUDIES have documented adverse effects of commonly prescribed pain medications on the cardiovascular system. One group of reports has demonstrated an increased risk of stroke and myocardial infarction in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain relief (5, 15, 18, 20, 34). These findings had a dramatic impact on large numbers of patients worldwide and resulted in the withdrawal of a commonly prescribed analgesic from the marketplace. In addition, a large clinical study has recently been reported, demonstrating that the use of prescription and over-the-counter NSAIDs increases mortality in patients who take these drugs after an acute myocardial infarction (AMI) (11).

Acetaminophen, the active ingredient in Tylenol, is a widely used drug that is well known for its analgesic and antipyretic properties. However, the cardiovascular effects of acetaminophen have not been fully assessed. Data are particularly lacking regarding the effect of acetaminophen in the setting of an AMI. Recently, the use of acetaminophen has been studied as a potential adjunct to reperfusion therapy for AMI (6, 16, 27). The results regarding the efficacy of acetaminophen in this setting are inconclusive and, in some cases, contradictory.

Using both large (ovine) and small (rabbit) collateral-deficient animal models of reperfused AMI, we studied the effects of acetaminophen on myocardial salvage, myocardial blood flow, ventricular function, hemodynamics, and apoptotic cell death. In the setting of an AMI, we sought to identify any potential harmful or cardioprotective effects of the drug.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Surgical protocol. Sixteen Dorset male hybrid sheep weighing 30–45 kg and twenty-two New Zealand White male rabbits weighing 3–4 kg were used in this study. Animals were treated under experimental protocols approved by the University of Pennsylvania's Institutional Animal Care and Use Committee and in compliance with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH Publications No. 85-23, Revised 1996).

Anesthesia was induced with thiopental sodium (10–15 mg/kg iv), and sheep were intubated, anesthetized with isoflurane (1.5–2%), and ventilated with oxygen (Drager anesthesia monitor, North American Drager, Telford, PA). Fluid-filled catheters were placed in a femoral artery and internal jugular vein for the continuous measurement of blood pressure and the administration of intravenous medications. A Swan-Ganz catheter (131h-7F, Baxter Healthcare, Irvine, CA) was introduced into the pulmonary artery through the internal jugular vein, and a high-fidelity pressure transducer (Spc-350S, Millar Instruments, Houston, TX) was inserted from the femoral artery into the left ventricle (LV). Animals underwent a left thoracotomy, and silicone vascular loops (Quest Medical Allen) were placed around the left anterior descending artery and its second diagonal branch 40% of the distance from the apex to the base of the heart. Occlusion of these arteries at these locations has produced a well-characterized model of anteroapical myocardial infarction in our laboratory (7, 8, 28).

In rabbits, anesthesia was induced with ketamine (50 mg/kg im), glycopyrrolate (0.2 mg/kg), and buprenorphine (0.05 mg/kg). Animals were intubated, anesthetized with isoflurane (0.25–1%), and ventilated with oxygen (Hallowell EMC model AWS, Pittsfield, MA). Fluid-filled catheters were introduced into a small auricular artery and vein and into the right jugular vein for the continuous measurement of blood pressure and the administration of intravenous medications. Additionally, a high-fidelity pressure transducer (SPR-524, Millar Instruments) was introduced through the right carotid artery into the LV. Animals underwent a left thoracotomy, and a coronary snare was constructed by placing a pledgeted suture (4-0 silk, U.S. Surgical, Norwalk, CT) around a large branch of the circumflex coronary artery at ~50% of the distance from base to apex of the heart.

A hyper-/hypothermia unit (Medi-Therm III, Gaymar Industries, Orchard Park, NY) was used to maintain core temperature of 38–40°C in sheep and 39–41°C in rabbits. Arterial blood gases were measured in all animals, and the mean pH was 7.40 ± 0.07 at the initiation of ischemia in rabbits and 7.38 ± 0.05 in sheep.

Experimental protocol. Sheep and rabbits were divided into control or treatment groups. After instrumentation, baseline hemodynamic data and echocardiographic measurements were recorded. Sheep (n = 8) and rabbits (n = 11) in the control group received an intravenous infusion of a 10% ethanol solution as a vehicle. Sheep (n = 8) in the treatment group received an intravenous infusion of 75 mg/kg of acetaminophen, dissolved in a 10% ethanol solution over 30 min. Rabbits (n = 11) in the treatment group received an intravenous infusion of 15 mg/kg of acetaminophen, dissolved in a 10% ethanol solution. All animals received either vehicle or acetaminophen infusions 30 min before coronary artery occlusion.

After repeat hemodynamic and echocardiographic measurements, heparin (10,000 U in sheep and 500 U/kg in rabbits) was administered. Additionally, a prophylactic intravenous anti-arrhythmic regimen of magnesium sulfate (1 g iv), amiodarone (150 mg iv), and lidocaine (3 mg/kg iv bolus, and then 2 mg/min infusion) was administered in the sheep model due to the high frequency of fatal arrhythmias after the induction of ischemia. The coronary snares were then tightened to produce an ischemic region of the LV. Ischemia was confirmed by a visible color change in the ischemic myocardial region, ST elevations on the electrocardiogram, and regional wall motion abnormalities on the echocardiogram. The ischemic period was 60 min in sheep and 30 min in rabbits. At the end of the ischemic period, coronary snares were loosened and the previously ischemic myocardium was reperfused for 3 h in all animals. The reperfused myocardium typically exhibited a visible hyperemic response. Hemodynamic measurements were recorded at 30-min intervals throughout the reperfusion period, and echocardiography was performed at 10 min and 165 min of reperfusion.

Analysis of area at risk and infarct size. At the completion of the protocol, the coronary snares were re-tightened, and vascular clamps were used to occlude the aorta, pulmonary artery, and inferior vena cava, and the right atrium was incised. Evans blue dye (1 ml/kg; Sigma; St. Louis, MO) was injected via the left atrium to delineate the ischemic myocardial area at risk (AR). All animals were euthanized via an injection of KCl into the left atrium, and the heart was explanted. The LV was sectioned perpendicular to its long axis into 6–8 slices (Fig. 1A). The thickness of each slice was measured with a digital micrometer, and all slices were photographed. Infarct area was delineated by photographing and measuring the slices after 20 min of incubation in 2% triphenyltetrazolium chloride at 37°C (Fig. 1B). All photographs were imported into an image analysis program (Image-Pro Plus, MediaCybernetics; Silver Spring, MD), and computerized planimetry was performed. The AR is expressed as a percentage of the LV, and the infarct size (I) is expressed as a percentage of the AR (I/AR).


Figure 1
View larger version (58K):
[in this window]
[in a new window]
  		Fig. 1. Sheep left ventricular (LV) sections sliced perpendicular to its long axis after staining with Evans blue dye (A) and triphenytetrazolium chloride (B).

 
Temperature and hemodynamic measurements. Arterial blood pressure, LV pressure, heart rate, surface ECG, and rectal temperature were continuously monitored (Hewlett-Packard 78534C; Palo Alto, CA) throughout the protocol in both species. Hemodynamic, heart rate, and temperature measurements were recorded at baseline, postdrug (vehicle or acetaminophen) infusion, 20 min of ischemia, and every 30 min during reperfusion (Sonometrics, London, Ontario, Canada). Cardiac output was measured in triplicate at each time point in sheep. The maximal rate of LV pressure increase (+dP/dtmax) and decrease (–dP/dtmax) over time were calculated at each time point in all animals.

Regional blood flow measurements. In the sheep, fifteen-million color-coded, 15.5-µm diameter NuFlow Fluorescent microspheres (IMT, Irvine, CA) were injected to validate the absence of collateral circulation and completeness of ischemia during coronary occlusion and to evaluate any effect of acetaminophen on the microvasculature. Injections were made at baseline, 30 min after coronary occlusion, and at 10 and 165 min after the onset of reperfusion. Reference blood samples were taken at all time points. Myocardial samples and reference blood samples were analyzed with the use of flow cytometry for micropshere content by IMT. Regional perfusion was calculated by using the following formula: Qm = (Cm x Qr)/Cr, where Qm is myocardial blood flow per gram (in ml·min–1·g–1) of sample, Cm is microsphere count per gram of tissue in sample, Qr is withdrawal rate of the reference blood sample (in ml/min), and Cr is microsphere count in the reference blood sample.

Echocardiography. Quantitative, two-dimensional, open-chest echocardiograms were performed at baseline, postdrug infusion, 20 min of ischemia, and 165 min of reperfusion in all animals. Images were obtained on a Philips 7500 ultrasound system using a 5-MHz (sheep) or 12-MHz (rabbits) transducer (model 770020A, Hewlett-Packard) with a custom-made offset device and recorded on 0.5-in. VHS videotape at 30 Hz (Panasonic AG-6300 VHS recorder). The transducer was placed at the cardiac apex, and two orthogonal long-axis views were recorded. LV end-systolic volume (LVESV) and LV end-diastolic volume (LVEDV) were calculated by using Simpson's rule. Ejection fraction (EF) was calculated from LVESV and LVEDV.

Sonomicrometry array localization. Sonomicrometry array localization (SAL) is an imaging technique that uses small piezoelectric transducers to permanently label specific locations of myocardium (14, 30). In 12 sheep, 14 transducers (2 mm in diameter) were inserted into the myocardium of the LV free wall to form a grid on the anterior LV. This array consisted of five transducers within the planned infarction, three transducers at the edge of the infarct, and six transducers placed 2 to 5 cm cephalad to the infarct demarcation line (Fig. 2). This grid was designed so that measurements of rectangular areas could be performed within the infarct, border zone (BZ), remote, and basal areas of the myocardium. Distance between all pairs of transducers (120 chord lengths) was measured once every 5 ms in real time (Sonometrics). With the use of multidimensional scaling, the location of each transducer in a single, three-dimensional (3-D) coordinate system was determined at end systole (ES) and end diastole (ED) (14). ED was identified as the peak of the QRS complex. ES was identified at the –dP/dtmax. With the use of 3-D transducer coordinates from SAL, rectangular areas were calculated at ES and ED for each serial time point. Fractional areal strain (FS) was calculated by subtracting ES area from ED area, then dividing by ED area. All values were normalized to their baseline values for each animal, and mean values were calculated.


Figure 2
View larger version (61K):
[in this window]
[in a new window]
  		Fig. 2. Schematic (A) and picture (B) of alignment of sonomicrometry crystals (positions represented by numbers 1–13) on LV in sheep.

 
In sito oligo ligation staining. The In Situ Oligo Ligation (ISOL) assay (Intergen No. 7200) was used to identify apoptotic cells. This assay utilizes T4 DNA ligase to bind synthetic biotinylated oligonucleotides to 3'-dT overhangs. Paraffin-embedded tissue was sectioned into 5-µm slices and deparaffinized by three changes of xylene, followed by three changes of absolute ethanol. Subsequently, endogenous peroxidase was quenched in 3% hydrogen peroxide in PBS. After the tissue sections were washed, they were treated with 20 µg/ml of proteinase K in PBS, washed again, and placed in an equilibration buffer. A solution of T4 DNA ligase and oligonucleotides was next applied to the slides and incubated overnight at 16–22°C. ApopTag detection of ligated oligonucleotides was accomplished by applying a streptavidin-peroxidase conjugate that was developed with diaminobenzidine. Finally, tissue sections were counterstained in hematoxylin.

Entire tissue sections were digitalized with a scanning microscope and analyzed with an image analysis software package (Image-Pro Plus, MediaCybernetics). ISOL-positive and ISOL-negative nuclei were counted in the AR from both control and acetaminophen-treated rabbits by two investigators in a blinded fashion. Results are expressed as a percentage of ISOL positive cells divided by the total number of cells in the AR.

Statistics. Measurements are reported as means ± SE. A one-way ANOVA was used for all comparisons between groups, and repeated-measures ANOVA was used for all comparisons within groups. All analyses were completed with the use of SPSS version 11.0 (SPSS, Chicago, IL). Statistically significant differences were established at P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
AR and infarct size measurements. The size of the ischemic myocardial AR between the control and treatment groups was similar in both sheep (23 ± 2% vs. 24 ± 2% with acetaminophen, P = 0.73) and rabbits (22 ± 1% vs. 23 ± 2% with acetaminophen, P = 0.51). In sheep, infarct size, expressed as a percentage of the AR (I/AR), was similar between the two groups (59 ± 7% vs. 64 ± 7% with acetaminophen, P = 0.64). In rabbits, acetaminophen showed a trend toward limiting infarct size (34 ± 7% vs. 50 ± 8%, P = 0.16; Fig. 3).


Figure 3
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3. Ischemic area at risk (AR) expressed as percentage of LV and the infarct size (I) expressed as a percentage of AR (I/AR). Sheep and rabbits were randomized into two groups and received either an ethanol vehicle or acetaminophen before undergoing ischemia and reperfusion. Comparisons between groups were not significantly different.

 
Temperature, blood pressure, and heart rate. Core temperatures were not significantly different between groups at any time point in either species. Acetaminophen had no significant effect on heart rate at any time point in either species. The mean arterial blood pressure increased significantly (74 ± 2 to 88 ± 6 mmHg, P = 0.05) after acetaminophen was given in sheep. There was no other blood pressure effect in sheep or rabbits (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. Temperature and hemodynamics of sheep and rabbits undergoing ischemia and reperfusion

 
Ventricular function measurements. Ventricular function data are summarized in Table 2. In sheep, the infusion of acetaminophen before ischemia significantly increased cardiac output compared with controls (5.1 ± 0.3 vs. 3.5 ± 0.4 l/min, P < 0.01). However, there was no other difference in cardiac output between groups at any other time point. In both sheep and rabbits, LV systolic and diastolic function, as assessed by +dP/dtmax and –dP/dtmax, were unaffected by the addition of acetaminophen (Fig. 4).


View this table:
[in this window]
[in a new window]
  		Table 2. Parameters of ventricular function in sheep and rabbits undergoing ischemia and reperfusion

 

Figure 4
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. Effects of acetaminophen and ethanol vehicle on LV systolic and diastolic function in sheep (A) and rabbits (B). Indexes of LV systolic maximal rate of LV pressure increase (+dP/dtmax) and diastolic pressure decrease over time (–dP/dtmax) function are shown at baseline, after infusion of ethanol or acetaminophen (Post-drug), at 20 min of ischemia, and after 165 min of reperfusion (Rep-165). LVEDV and LVESV, LV end-diastolic and -systolic volumes, respectively. Comparisons between groups in either animal were not significantly different at any time point. *P < 0.05, from baseline values in acetaminophen-treated rabbits.

 
Apoptosis. The effect of acetaminophen on apoptotic cell death was studied in the rabbit experiments by the use of the ISOL technique, a highly specific test for the DNA cleavage fragments characteristic of apoptotic cell death (19). Despite the trend toward a reduction in infarct size in the acetaminophen group, there was no significant difference in the percentage of ISOL-positive cells between the two groups (6.0 ± 1.6% vs. 7.1 ± 2.2% with acetaminophen, P = 0.73).

Echocardiographic data. Baseline echocardiograms demonstrated normal wall motion of the anteroapical region of the heart in all animals. Images obtained after coronary occlusion confirmed a loss of apical contractility in the AR in all animals of both species. Elevations in LVESV and LVEDV were observed in all animals during the period of coronary occlusion, confirming significant ventricular dysfunction during the ischemic period (Fig. 5). Comparisons of LVESV, LVEDV, and EF between groups did not reveal any differences in animals receiving acetaminophen at any time point in either species.


Figure 5
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 5. Effects of acetaminophen and ethanol vehicle on LVEDV and LVESV as determined by serial, open-chest, quantitative, two-dimensional echocardiography in sheep (A) and rabbits (B). Comparisons between groups in either animal were not significantly different at any time point. *P < 0.05, from baseline values in vehicle-treated rabbits.

 
Regional blood flow. Myocardial ischemia and the absence of collateral circulation were confirmed by the reduction in regional blood flow in the AR to ≤4% of baseline values in both vehicle and acetaminophen-treated sheep. A hyperemic response was observed at the onset of reperfusion, but after 165 min of reperfusion, regional blood flow to the AR had fallen to 49 ± 11% in the vehicle group and 42 ± 16% in the acetaminophen group (P = 0.74). The addition of acetaminophen had no significant effect on regional blood flow at any time point (Fig. 6).


Figure 6
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 6. Effects of acetaminophen and ethanol vehicle on regional blood flow (RBF) in AR in sheep. Measurements were taken at baseline, after 20 min of ischemia, and after 10 min of reperfusion (Rep-10) and Rep-165. Comparisons between groups were not significantly different at any time point. *P < 0.05, from baseline values. **P < 0.05, from ischemia values. #P < 0.05, from immediate reperfusion values.

 
SAL. Normalized FS values for the myocardium immediately adjacent to the AR or BZ were analyzed for six sheep in each group. FS in the BZ was attenuated with ischemia and improved during reperfusion in both groups. There was a trend toward improved FS in the BZ during ischemia in sheep treated with acetaminophen (P = 0.11) but no significant differences at any other time point (Fig. 7).


Figure 7
View larger version (14K):
[in this window]
[in a new window]
  		Fig. 7. Effects of acetaminophen and ethanol on fractional areal strain of border zone myocardium area as determined by sonomicrometry in sheep. Measurements were taken at baseline, after infusion of ethanol or acetaminophen (Post-drug), at 20 min of ischemia, and Rep-165. Comparisons between groups were not significantly different. *P < 0.05, from baseline values in vehicle-treated sheep.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Our investigation involved two different in vivo models of collateral, deficient myocardial ischemia and reperfusion that reliably simulate reperfusion therapy for AMI. Our results support the conclusion that in the setting of AMI, acetaminophen has a neutral effect on infarct size, myocardial blood flow, myocyte apoptosis, hemodynamics, and ventricular function.

We demonstrated a small but statistically significant increase in cardiac output and mean arterial pressure after acetaminophen was administered in sheep. This effect was abolished during the ischemia and reperfusion time periods. No difference in any other hemodynamic parameter was detected at any other time point in sheep. Similar inotropic effects could not be demonstrated in the rabbit. Using sonomicrometry, we also demonstrated a nonsignificant trend toward improvement in BZ contraction during ischemia but not immediately after drug delivery before ischemia or after reperfusion in sheep. The small and short-lived changes in cardiac output and mean arterial pressure in sheep and the lack of any hemodynamic effect in rabbits suggest that acetaminophen may have, at most, an exceedingly mild positive inotropic effect. These results are similar to those reported by Merrill et al. (27) in the dog. Merrill and colleagues (25, 26) have demonstrated that acetaminophen has antioxidant properties in the myocardium; however, little else is known of the effects of acetaminophen on myocardial function. Because we did not hypothesize that acetaminophen would have an effect on myocardial performance beyond myocardial salvage, our experiment was not designed to assess mechanistic questions regarding acetaminophen and myocardial contractility.

Since its introduction into western medicine in 1893, acetaminophen has been used primarily as an antipyretic and analgesic (23). It is a phenol that possesses antioxidant properties and can also inhibit prostaglandin synthesis through the inhibition of COX-3, an isoform of cyclooxygenase (2). It should be noted that acetaminophen is a weak inhibitor of COX-1 and COX-2 cyclooxygenases, which are the predominant isoforms inhibited by the anti-inflammatory medications recently discovered to increase the risk of stroke and myocardial infarction (2, 15). The primary mechanism by which acetaminophen exerts its antipyretic and analgesic effects has yet to be definitively elucidated.

Over the last decade, off-label uses of acetaminophen for purposes other than pain relief have been reported. In human and canine studies of renal function, acetaminophen has been shown to reduce prostaglandin synthesis, renal blood flow, and glomerular filtration (4, 10). In a gastric model of ischemia-reperfusion, acetaminophen has been shown to preserve gastric mucosa by blocking hydroxyl radical-induced cellular damage (29). Acetaminophen has also been shown to have antioxidative effects in the myocardium of several mammalian species (25, 27). This antioxidant property has lead to the hypothesis that acetaminophen might have cardioprotective properties by preventing oxygen radical-induced reperfusion injury.

Recently, there have been conflicting reports regarding the effects of acetaminophen on ventricular function and myocardial salvage in the setting of reperfused AMI (6, 16, 27). Given the wide use of acetaminophen as an over-the-counter analgesic and antipyretic, the prevalence of undetected coronary disease, and the increasing use of reperfusion therapy to treat AMI, it is important to establish the safety and adjunctive benefits of the drug in this critically ill group of patients.

Data supporting cardioprotective effects of acetaminophen primarily come from the work of Merrill and colleagues (12, 13, 24–27, 31). In an isolated guinea pig heart model of myocardial ischemia and reperfusion, these investigators reported that acetaminophen-treated animals had preserved ventricular function during reperfusion compared with controls (25). Recently, Merrill and colleagues reported a 22% reduction in infarct size in an intact canine model of ischemia and reperfusion (27). In contrast to these findings, Kloner and colleagues (6, 16) have reported a neutral effect of acetaminophen on infarct size, regional myocardial blood flow, and ischemic preconditioning. This work was performed in rabbit and rat models of myocardial ischemia and reperfusion.

The differences in the animal models employed in the above cited studies may explain the inconsistent results reported by the two groups. Merrill's use of the intact collateral-rich dog heart may be less clinically relevant than the intact small animal collateral-deficient models used by Kloner's group. The dog, unlike humans, pigs, rabbits, and sheep, has extensive preformed epicardial collaterals that prevent absolute ischemia within the AR (9, 21, 22). The work of Kloner's group is limited by the exclusive use of small animal models that are generally less tolerant of ischemia than large animal preparations (17). To address these limitations, we utilized intact large (sheep) and small (rabbit) animal collateral deficient models that closely replicate the clinical scenario of reperfused AMI.

Our results are, generally, more consistent with the findings reported by Kloner and colleagues. Possible explanations for the differing results of Merrill and colleagues may be related to dosage and the timing of acetaminophen administration. Hale and Kloner (16) showed no effect on infarct size with the use of a dose of 75 mg/kg, administered either before or during ischemia in rabbits. In the lone in vivo study showing a reduction in infarct size, Merrill et al. used a dose of 15 mg/kg of acetaminophen administered just before the onset of 60 min of ischemia and another 15 mg/kg dose after 90 min of reperfusion in dogs. The authors speculated that myocardial salvage effects of acetaminophen were related to its antioxidant properties, because acetaminophen-treated animals had significantly decreased circulating plasma concentrations of peroxynitrite during ischemia and reperfusion (27). We used a dose of 15 mg/kg in rabbits because it is the maximum-recommended single dose of acetaminophen. In the sheep we used 75 mg/kg, which is, depending on the animal's size, 60% to 80% of the maximum daily human dose of 4 g. We chose this dose in an attempt to maximize the cardioprotective benefit while at the same time minimizing the potential for toxicity. This dose was also chosen to maximize the clinical relevance of the experiment by employing a single dose that would be considered clinically safe for use in patients. Finally, a higher dose was used in the sheep experiments because an assessment of myocardial perfusion was planned, and previous studies (24) had demonstrated a modest, but significant, coronary vasoconstrictive effect of the drug.

In this experiment, the drug was always infused intravenously 30 min before coronary artery occlusion. It is possible that the additional dose given by Merrill's group after reperfusion contributed to the difference in results; however, the relatively long half-life of acetaminophen [150 min (32)] and the relatively large doses used in all the studies reported to date argue against this explanation.

We also examined the effect of acetaminophen on coronary blood flow. It is known that prostaglandins are released from ischemic myocardium and contribute to myocardial protection during reperfusion by increasing coronary blood flow (3, 33). This cardioprotective role of prostaglandins is not insignificant. It has been demonstrated in an ischemia-reperfusion model that mice lacking prostaglandin receptors have an increased myocardial infarct size compared with wild-type mice (36). Acetaminophen, which can inhibit prostaglandin synthesis, has been shown to modestly but significantly increase coronary vascular resistance and decrease coronary perfusion at doses at the upper limits of the human therapeutic range (24). Therefore, it was possible that high doses of the drug could significantly attenuate coronary blood flow and increase infarct size. This was not found to be the case in our study, because the results of our regional blood flow study showed that acetaminophen had no adverse or salutary effects on coronary blood flow in the AR at any time point in the study (Fig. 6).

In the current study, acetaminophen was dissolved in a 10% ethanol solution for intravenous administration. It has been shown that acute ethanol exposure does not affect infarct size after myocardial ischemia and reperfusion in a rabbit model, similar to the one used in this study (1). Also, it has been shown that short-term administration of alcohol had no effect on ventricular function after myocardial ischemia and reperfusion in a conscious canine model (35). Nevertheless, this is another difference between the current study and the work showing the cardioprotective benefits of acetaminophen, which used a physiological salt solution as the vehicle for acetaminophen. Therefore, it is possible that the effect of ethanol on the myocardium or its interaction with acetaminophen could mask potential cardioprotective effects from acetaminophen.

In summary, the current report adds to a small but growing body of data on the effects of acetaminophen in the setting of a reperfused AMI. In both large and small animal models of myocardial ischemia and reperfusion, we have shown that acetaminophen has a neutral effect on hemodynamics, heart rate, myocyte apoptosis, and myocardial infarct size. These results are both in concordance and in conflict with existing data in the literature. Despite the discrepancies between the studies published to date, none have demonstrated any harmful effects of the drug during myocardial ischemia or reperfusion. The recent awareness that COX-2 inhibitors increase the risk of suffering an AMI and the even more recent discovery that many NSAIDs are associated with decreased long-term survival after an AMI (11) highlight the importance and the clinical relevance of these experiments and demand a direct comparison of acetaminophen with commonly used NSAIDs in similar experiments to those described above.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Heart, Lung, and Blood Institute (Bethesda, MD) Grants HL-63954, HL-71137, and HL-76560 and a grant from McNeil Consumer and Specialty Pharmaceuticals (Fort Washington, PA).


   FOOTNOTES
 

Address for reprint requests and other correspondence: R. C. Gorman, Harrison Dept. of Surgical Research, Univ. of Pennsylvania School of Medicine, 313 Stemmler Hall, 36th and Hamilton Walk, Philadelphia, PA 19104-4283 (e-mail: gormanr{at}uphs.upenn.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* B. G. Leshnower and H. Sakamoto contributed equally to this work. Back


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Bellows SD, Hale SL, and Kloner RA. Acute ethanol does not protect against ischemic/reperfusion injury in rabbit myocardium. J Thromb Thrombolysis 3: 181–184, 1996.[Medline]
  2. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, and Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–13931, 2002.[Abstract/Free Full Text]
  3. Coker SJ, Parratt JR, Ledingham IM, and Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291: 323–324, 1981.[CrossRef][Medline]
  4. Colletti AE, Vogl HW, Rahe T, and Zambraski EJ. Effects of acetaminophen and ibuprofen on renal function in anesthetized normal and sodium-depleted dogs. J Appl Physiol 86: 592–597, 1999.[Abstract/Free Full Text]
  5. Couzin J. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science 307: 1183–1185, 2005.
  6. Dai W and Kloner RA. Effects of acetaminophen on myocardial infarct size in rats. J Cardiovasc Pharmacol Ther 8: 277–284, 2003.[Abstract/Free Full Text]
  7. Enomoto Y, Gorman JH III, Moainie SL, Guy TS, Jackson BM, Parish LM, Plappert T, Zeeshan A, St. John-Sutton MG, and Gorman RC. Surgical treatment of ischemic mitral regurgitation might not influence ventricular remodeling. J Thorac Cardiovasc Surg 129: 504–511, 2005.[Abstract/Free Full Text]
  8. Enomoto Y, Gorman JH III, Moainie SL, Jackson BM, Parish LM, Plappert T, Zeeshan A, St. John-Sutton MG, and Gorman RC. Early ventricular restraint after myocardial infarction: extent of the wrap determines the outcome of remodeling. Ann Thorac Surg 79: 881–887, 2005.[Abstract/Free Full Text]
  9. Factor SM, Okun EM, Minase T, and Kirk ES. The microcirculation of the human heart: end-capillary loops with discrete perfusion fields. Circulation 66: 1241–1248, 1982.[Abstract/Free Full Text]
  10. Farquhar WB, Morgan AL, Zambraski EJ, and Kenney WL. Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. J Appl Physiol 86: 598–604, 1999.[Abstract/Free Full Text]
  11. Gislason G, Jacobson S, Buch P, Rasmussen J, Friberg J, Abildstrom S, and Torp-Pederson C. Increased mortality related to treatment with selective cyclo-oxygenase-2 inhibitors and non steroidal anti-inflammatory drugs after acute myocardial infarction (Abstract). Circulation 112, Supplement II: II372, 2005.
  12. Golfetti R, Rork T, and Merrill G. Chronically administered acetaminophen and the ischemia/reperfused myocardium. Exp Biol Med (Maywood) 228: 674–682, 2003.[Abstract/Free Full Text]
  13. Golfetti R, VanDyke K, Rork T, Spiler N, and Merrill G. Acetaminophen in the post-ischemia reperfused myocardium. Exp Biol Med (Maywood) 227: 1031–1037, 2002.[Abstract/Free Full Text]
  14. Gorman JH III, Gupta KB, Streicher JT, Gorman RC, Jackson BM, Ratcliffe MB, Bogen DK, and Edmunds LH Jr. Dynamic three-dimensional imaging of the mitral valve and left ventricle by rapid sonomicrometry array localization. J Thorac Cardiovasc Surg 112: 712–726, 1996.[Abstract/Free Full Text]
  15. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, and Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481, 2005.[ISI][Medline]
  16. Hale SL and Kloner RA. Acetaminophen and experimental acute myocardial infarction. Cardiovasc Drugs Ther 18: 121–125, 2004.[CrossRef][ISI][Medline]
  17. Jugdutt BI, Joljart MJ, and Khan MI. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation 94: 94–101, 1996.[Abstract/Free Full Text]
  18. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, and Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–2029, 2004.[CrossRef][ISI][Medline]
  19. Lesauskaite V, Epistolato MC, Ivanoviene L, and Tanganelli P. Apoptosis of cardiomyocytes in explanted and transplanted hearts. Comparison of results from in situ TUNEL, ISEL, and ISOL reactions. Am J Clin Pathol 121: 108–116, 2004.[CrossRef][ISI][Medline]
  20. Lievre M and Abadie E. Discontinuation of Vioxx. Lancet 365: 23–27, 2005.[ISI][Medline]
  21. Markovitz LJ, Savage EB, Ratcliffe MB, Bavaria JE, Kreiner G, Iozzo RV, Hargrove WC III, Bogen DK, and Edmunds LH Jr. Large animal model of left ventricular aneurysm. Ann Thorac Surg 48: 838–845, 1989.[Abstract]
  22. Maxwell MP, Hearse DJ, and Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 21: 737–746, 1987.[ISI][Medline]
  23. Mehring VI. Beitrage zur Kenntniss der antipyretica. Ther Monatsschrift 7: 577–579, 1893.
  24. Merrill G, McConnell P, Vandyke K, and Powell S. Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 280: H2631–H2638, 2001.[Abstract/Free Full Text]
  25. Merrill GF. Acetaminophen and low-flow myocardial ischemia: efficacy and antioxidant mechanisms. Am J Physiol Heart Circ Physiol 282: H1341–H1349, 2002.[Abstract/Free Full Text]
  26. Merrill GF and Goldberg E. Antioxidant properties of acetaminophen and cardioprotection. Basic Res Cardiol 96: 423–430, 2001.[CrossRef][ISI][Medline]
  27. Merrill GF, Rork TH, Spiler NM, and Golfetti R. Acetaminophen and myocardial infarction in dogs. Am J Physiol Heart Circ Physiol 287: H1913–H1920, 2004.[Abstract/Free Full Text]
  28. Moainie SL, Gorman JH III, Guy TS, Bowen FW III, Jackson BM, Plappert T, Narula N, St. John-Sutton MG, Narula J, Edmunds LH Jr, and Gorman RC. An ovine model of postinfarction dilated cardiomyopathy. Ann Thorac Surg 74: 753–760, 2002.[Abstract/Free Full Text]
  29. Nakamoto K, Kamisaki Y, Wada K, Kawasaki H, and Itoh T. Protective effect of acetaminophen against acute gastric mucosal lesions induced by ischemia-reperfusion in the rat. Pharmacology 54: 203–210, 1997.[ISI][Medline]
  30. Ratcliffe MB, Gupta KB, Streicher JT, Savage EB, Bogen DK, and Edmunds LH Jr. Use of sonomicrometry and multidimensional scaling to determine the three-dimensional coordinates of multiple cardiac locations: feasibility and initial implementation. IEEE Trans Biomed Eng 42: 587–598, 1995.[CrossRef][ISI][Medline]
  31. Rork TH, Van Dyke K, Spiler NM, and Merrill GF. Acetaminophen in the hypoxic and reoxygenated guinea pig myocardium. Exp Biol Med (Maywood) 229: 1154–1161, 2004.[Abstract/Free Full Text]
  32. Stork CM, Rees S, Howland MA, Kaplan L, Goldfrank L, and Hoffman RS. Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. J Toxicol Clin Toxicol 34: 157–162, 1996.[ISI][Medline]
  33. Thiemermann C and Zacharowski K. Selective activation of E-type prostanoid(3)-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins. Pharmacol Ther 87: 61–67, 2000.[CrossRef][ISI][Medline]
  34. Topol EJ. Failing the public health–rofecoxib, Merck, and the FDA. N Engl J Med 351: 1707–1709, 2004.[Free Full Text]
  35. Weber TP, Hartlage MA, Rolf N, Booke M, Berendes E, Van Aken H, and Meissner A. Short-term administration of ethanol does not affect functional recovery from myocardial stunning in awake dogs. Anesth Analg 96: 665–672, 2003.[Abstract/Free Full Text]
  36. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, Takahata O, Yamada T, Murata T, Narumiya S, and Ushikubi F. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104: 2210–2215, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
G. F. Merrill, J. H. Merrill, R. Golfetti, K. M. Jaques, N. S. Hadzimichalis, S. S. Baliga, and T. H. Rork
Antiarrhythmic Properties of Acetaminophen in the Dog
Experimental Biology and Medicine, October 1, 2007; 232(9): 1245 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
B. G. Leshnower, H. Sakamoto, H. Hamamoto, A. Zeeshan, J. H. Gorman III, and R. C. Gorman
Progression of myocardial injury during coronary occlusion in the collateral-deficient heart: a non-wavefront phenomenon
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1799 - H1804.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leshnower, B. G.
Right arrow Articles by Gorman, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leshnower, B. G.
Right arrow Articles by Gorman, R. C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.